{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:43:47Z","timestamp":1793853827405,"version":"4.6.1"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"\n Importance<\/jats:title>\n Rituximab has emerged as a front-line therapy for pemphigus, but prognostic factors for achieving complete remission off therapy (CROT) with oral systemic agents remain unknown.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To describe rates of CROT and relapse and identify prognostic factors for achieving CROT after rituximab therapy for pemphigus.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A single-center, retrospective, cohort study was conducted at the University of Pennsylvania including 112 patients with pemphigus treated with rituximab with at least 12 months\u2019 clinical follow-up after the start of rituximab therapy. Multivariate regression analysis of factors predictive of CROT and Kaplan-Meier analysis of disease relapse were conducted. The study included patients treated with rituximab from March 15, 2005, until December 19, 2016. Data analysis was performed from December 2017 to June 2018.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary study outcome was CROT after 1 cycle. Secondary study outcomes included rate of CROT or the composite end point of CROT or complete remission on minimal therapy after 1 or more cycle, and median time to relapse. Multivariate regression analysis for prognostic variables for CROT, including age, sex, pemphigus subtype, body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), disease duration, and dosing regimen, was performed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 112 patients with pemphigus with median 37.8 months (range, 12.1-130.7) follow-up after rituximab therapy were identified. Of these, 65 were women (58.0%). At the time of first rituximab infusion, median age was 52.3 years (range, 20.0-89.3). Including patients who received multiple cycles of rituximab, 79 patients (70.5%) achieved CROT after a median time of 10.5 months (range, 2.0-49.8), and 36 of 72 patients (50.0%) subsequently experienced relapse after a median of 23.3 months (interquartile range, 10.8-50.4 months). Considering only the first cycle of rituximab, 54 patients (48.2%) achieved CROT. Controlling for age, sex, pemphigus subtype, BMI, and disease duration, patients who received lymphoma vs rheumatoid arthritis dosing were 2.70-fold more likely to achieve CROT (odds ratio [OR], 2.70; 95% CI, 1.03-7.12;\n P<\/jats:italic>\n \u2009=\u2009.04). Increasing age was associated with significant increases in achieving CROT (Wald test for trend,\n P<\/jats:italic>\n \u2009=\u2009.01), whereas BMI greater than or equal to 35 was associated with a 0.14 OR (95% CI, 0.03-0.63;\n P<\/jats:italic>\n \u2009=\u2009.01) for achieving CROT, regardless of the dosing regimen. In multivariate analysis, there was no significant difference in CROT rates with sex (OR, 1.01; 95% CI, 0.42-2.50;\n P<\/jats:italic>\n \u2009=\u2009.97), pemphigus subtype (OR, 0.37; 95% CI, 0.09-1.51;\n P<\/jats:italic>\n \u2009=\u2009.17), or disease duration (OR, 0.99; 95% CI, 0.98-1.00;\n P<\/jats:italic>\n \u2009=\u2009.09).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Lymphoma dosing and older age may be associated with CROT and BMI greater than or equal to 35 may be a negative prognostic factor for CROT after rituximab therapy for pemphigus. These findings help inform clinical expectations and merit evaluation in future prospective clinical trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2019.3236","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T13:31:28Z","timestamp":1571837488000},"page":"1404","source":"Crossref","is-referenced-by-count":64,"title":["Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus"],"prefix":"10.1001","volume":"155","author":[{"given":"Carolyn J.","family":"Kushner","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napatra","family":"Tovanabutra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"},{"name":"Division of Dermatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi190055r1","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus.","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"doi190055r2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus.","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"issue":"17","key":"doi190055r3","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"issue":"175","key":"doi190055r4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"issue":"10083","key":"doi190055r5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"doi190055r6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1586\/eci.11.22","article-title":"Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.","volume":"7","author":"Feldman","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"doi190055r7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi190055r8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"doi190055r10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2334-4-42","article-title":"Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia: a strategy for prevention.","volume":"4","author":"Sowden","year":"2004","journal-title":"BMC Infect Dis"},{"issue":"3","key":"doi190055r11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1046\/j.1365-2133.1999.03052.x","article-title":"Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases.","volume":"141","author":"Raychaudhuri","year":"1999","journal-title":"Br J Dermatol"},{"issue":"11","key":"doi190055r12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jamadermatol.2017.2808","article-title":"Determining the incidence of Pneumocystis pneumonia in patients with autoimmune blistering diseases not receiving routine prophylaxis.","volume":"153","author":"Amber","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"8","key":"doi190055r13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ijd.13231","article-title":"Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis.","volume":"55","author":"Gonzalez Santiago","year":"2016","journal-title":"Int J Dermatol"},{"issue":"9","key":"doi190055r14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study.","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern Med"},{"key":"doi190055r15","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"doi190055r16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG+ B-cell clones in pemphigus patients over years.","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"12","key":"doi190055r17","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-Cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses.","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi190055r18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/sji.12413","article-title":"Effects of ageing on the immune system: infants to elderly.","volume":"83","author":"Valiathan","year":"2016","journal-title":"Scand J Immunol"},{"issue":"6","key":"doi190055r19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jbspin.2015.02.011","article-title":"Body mass index and response to rituximab in rheumatoid arthritis.","volume":"82","author":"Ottaviani","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"2","key":"doi190055r20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.13040\/IJPSR.0975-8232","article-title":"High body mass index and reduction of response to rituximab in patients with rheumatoid arthritis.","volume":"8","author":"Mshimesh","year":"2017","journal-title":"Int J Pharm Sci Res"},{"issue":"5","key":"doi190055r21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/1078155215599669","article-title":"Comparison of two different formulas for body surface area in adults at extremes of height and weight.","volume":"22","author":"Fancher","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"doi190055r22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12026-018-8989-4","article-title":"Impaired natural killer cell subset phenotypes in human obesity.","volume":"66","author":"B\u00e4hr","year":"2018","journal-title":"Immunol Res"},{"issue":"3","key":"doi190055r24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","article-title":"Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus.","volume":"130","author":"Lunardon","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi190055r25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"21","key":"doi190055r26","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"doi190055r23","year":"2018"},{"key":"doi190055r9","unstructured":"US Food & Drug Administration. Code of Federal Regulations Title 21. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32. Accessed September 25, 2019."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2753265\/jamadermatology_kushner_2019_oi_190055_1744220608.34127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:00:18Z","timestamp":1744207218000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2753265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.3236","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}